3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
3
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pathologic Complete Response
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
6
Doxorubicin
6
Gemcitabine
4
Bevacizumab
4
pembrolizumab
3
pazopanib
3
durvalumab
3
Sorafenib
3
Docetaxel
3
trebananib
2
spartalizumab
2
cemiplimab
2
brostallicin
2
Propranolol
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Imatinib Mesylate
2
Ifosfamide
2
Carboplatin
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trastuzumab duocarmazine
1
temsirolimus
1
talimogene laherparepvec
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hemangiosarcoma
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled